nodes	percent_of_prediction	percent_of_DWPC	metapath
Midazolam—CYP4B1—urinary bladder cancer	0.675	1	CbGaD
Midazolam—CYP2B6—Thiotepa—urinary bladder cancer	0.0445	0.268	CbGbCtD
Midazolam—ABCB1—Mitomycin—urinary bladder cancer	0.0301	0.181	CbGbCtD
Midazolam—CYP3A4—Thiotepa—urinary bladder cancer	0.0137	0.0822	CbGbCtD
Midazolam—CYP2B6—Cisplatin—urinary bladder cancer	0.0123	0.0739	CbGbCtD
Midazolam—CYP2E1—Etoposide—urinary bladder cancer	0.0122	0.0736	CbGbCtD
Midazolam—CYP3A5—Etoposide—urinary bladder cancer	0.0095	0.0572	CbGbCtD
Midazolam—ABCB1—Gemcitabine—urinary bladder cancer	0.00866	0.0521	CbGbCtD
Midazolam—CYP2B6—Doxorubicin—urinary bladder cancer	0.00822	0.0495	CbGbCtD
Midazolam—ABCB1—Cisplatin—urinary bladder cancer	0.00629	0.0379	CbGbCtD
Midazolam—ABCB1—Etoposide—urinary bladder cancer	0.00618	0.0372	CbGbCtD
Midazolam—ABCB1—Doxorubicin—urinary bladder cancer	0.00422	0.0254	CbGbCtD
Midazolam—ABCB1—Methotrexate—urinary bladder cancer	0.00408	0.0246	CbGbCtD
Midazolam—CYP3A4—Etoposide—urinary bladder cancer	0.0037	0.0223	CbGbCtD
Midazolam—CYP3A4—Doxorubicin—urinary bladder cancer	0.00253	0.0152	CbGbCtD
Midazolam—CYP4B1—prostate gland—urinary bladder cancer	0.00164	0.0781	CbGeAlD
Midazolam—UGT1A4—renal system—urinary bladder cancer	0.00113	0.054	CbGeAlD
Midazolam—CYP4B1—urethra—urinary bladder cancer	0.0011	0.0523	CbGeAlD
Midazolam—CYP2E1—urine—urinary bladder cancer	0.00106	0.0505	CbGeAlD
Midazolam—GABRP—prostate gland—urinary bladder cancer	0.000921	0.044	CbGeAlD
Midazolam—CYP4B1—female reproductive system—urinary bladder cancer	0.000893	0.0427	CbGeAlD
Midazolam—CYP3A4—urine—urinary bladder cancer	0.00085	0.0406	CbGeAlD
Midazolam—CYP4B1—vagina—urinary bladder cancer	0.000808	0.0386	CbGeAlD
Midazolam—GABRE—prostate gland—urinary bladder cancer	0.000703	0.0336	CbGeAlD
Midazolam—Clonazepam—NAT2—urinary bladder cancer	0.000682	0.394	CrCbGaD
Midazolam—GABRP—urethra—urinary bladder cancer	0.000617	0.0295	CbGeAlD
Midazolam—GABRB3—prostate gland—urinary bladder cancer	0.000596	0.0285	CbGeAlD
Midazolam—GABRE—seminal vesicle—urinary bladder cancer	0.000595	0.0284	CbGeAlD
Midazolam—Flunitrazepam—UGT2B7—urinary bladder cancer	0.000589	0.341	CrCbGaD
Midazolam—CYP4B1—lymph node—urinary bladder cancer	0.000523	0.025	CbGeAlD
Midazolam—GABRB1—vagina—urinary bladder cancer	0.000508	0.0242	CbGeAlD
Midazolam—GABRP—female reproductive system—urinary bladder cancer	0.000503	0.024	CbGeAlD
Midazolam—GABRE—urethra—urinary bladder cancer	0.000471	0.0225	CbGeAlD
Midazolam—Oxazepam—UGT2B7—urinary bladder cancer	0.000458	0.265	CrCbGaD
Midazolam—SLC22A1—renal system—urinary bladder cancer	0.000456	0.0218	CbGeAlD
Midazolam—GABRP—vagina—urinary bladder cancer	0.000455	0.0217	CbGeAlD
Midazolam—GABRR2—lymph node—urinary bladder cancer	0.000421	0.0201	CbGeAlD
Midazolam—CYP3A5—prostate gland—urinary bladder cancer	0.000407	0.0194	CbGeAlD
Midazolam—GABRE—female reproductive system—urinary bladder cancer	0.000384	0.0183	CbGeAlD
Midazolam—CYP2E1—prostate gland—urinary bladder cancer	0.000379	0.0181	CbGeAlD
Midazolam—GABRA2—vagina—urinary bladder cancer	0.00035	0.0167	CbGeAlD
Midazolam—GABRE—vagina—urinary bladder cancer	0.000347	0.0166	CbGeAlD
Midazolam—SLC22A1—vagina—urinary bladder cancer	0.000331	0.0158	CbGeAlD
Midazolam—GABRB3—female reproductive system—urinary bladder cancer	0.000325	0.0155	CbGeAlD
Midazolam—CYP2E1—seminal vesicle—urinary bladder cancer	0.000321	0.0153	CbGeAlD
Midazolam—CYP3A5—renal system—urinary bladder cancer	0.000277	0.0132	CbGeAlD
Midazolam—CYP2B6—renal system—urinary bladder cancer	0.000275	0.0132	CbGeAlD
Midazolam—CYP2E1—renal system—urinary bladder cancer	0.000259	0.0123	CbGeAlD
Midazolam—CYP2E1—urethra—urinary bladder cancer	0.000254	0.0121	CbGeAlD
Midazolam—GABRA2—lymph node—urinary bladder cancer	0.000226	0.0108	CbGeAlD
Midazolam—GABRE—lymph node—urinary bladder cancer	0.000225	0.0107	CbGeAlD
Midazolam—CYP2B6—female reproductive system—urinary bladder cancer	0.000221	0.0105	CbGeAlD
Midazolam—ABCB1—prostate gland—urinary bladder cancer	0.000216	0.0103	CbGeAlD
Midazolam—CYP3A4—renal system—urinary bladder cancer	0.000208	0.00993	CbGeAlD
Midazolam—CYP2E1—female reproductive system—urinary bladder cancer	0.000207	0.00989	CbGeAlD
Midazolam—CYP3A5—vagina—urinary bladder cancer	0.000201	0.00959	CbGeAlD
Midazolam—CYP2B6—vagina—urinary bladder cancer	0.0002	0.00953	CbGeAlD
Midazolam—ABCB1—seminal vesicle—urinary bladder cancer	0.000183	0.00873	CbGeAlD
Midazolam—CYP3A4—female reproductive system—urinary bladder cancer	0.000167	0.00796	CbGeAlD
Midazolam—ABCB1—epithelium—urinary bladder cancer	0.000159	0.00758	CbGeAlD
Midazolam—ABCB1—renal system—urinary bladder cancer	0.000147	0.00703	CbGeAlD
Midazolam—ABCB1—urethra—urinary bladder cancer	0.000145	0.00691	CbGeAlD
Midazolam—Lethargy—Epirubicin—urinary bladder cancer	0.000128	0.00156	CcSEcCtD
Midazolam—Irritability—Methotrexate—urinary bladder cancer	0.000128	0.00156	CcSEcCtD
Midazolam—Confusional state—Fluorouracil—urinary bladder cancer	0.000128	0.00156	CcSEcCtD
Midazolam—Mood swings—Methotrexate—urinary bladder cancer	0.000127	0.00155	CcSEcCtD
Midazolam—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000127	0.00155	CcSEcCtD
Midazolam—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000127	0.00154	CcSEcCtD
Midazolam—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000126	0.00154	CcSEcCtD
Midazolam—Ataxia—Methotrexate—urinary bladder cancer	0.000126	0.00154	CcSEcCtD
Midazolam—Osteoarthritis—Epirubicin—urinary bladder cancer	0.000126	0.00153	CcSEcCtD
Midazolam—Diplopia—Epirubicin—urinary bladder cancer	0.000126	0.00153	CcSEcCtD
Midazolam—Skin disorder—Gemcitabine—urinary bladder cancer	0.000125	0.00153	CcSEcCtD
Midazolam—Anxiety—Cisplatin—urinary bladder cancer	0.000125	0.00153	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000125	0.00152	CcSEcCtD
Midazolam—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000124	0.00152	CcSEcCtD
Midazolam—Tachycardia—Fluorouracil—urinary bladder cancer	0.000124	0.00151	CcSEcCtD
Midazolam—Affect lability—Epirubicin—urinary bladder cancer	0.000124	0.00151	CcSEcCtD
Midazolam—Urticaria—Thiotepa—urinary bladder cancer	0.000122	0.00149	CcSEcCtD
Midazolam—Vertigo—Etoposide—urinary bladder cancer	0.000121	0.00148	CcSEcCtD
Midazolam—Hypotension—Gemcitabine—urinary bladder cancer	0.000121	0.00147	CcSEcCtD
Midazolam—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00012	0.00147	CcSEcCtD
Midazolam—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.00012	0.00147	CcSEcCtD
Midazolam—Cardiac arrest—Epirubicin—urinary bladder cancer	0.00012	0.00146	CcSEcCtD
Midazolam—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000119	0.00145	CcSEcCtD
Midazolam—Mood swings—Epirubicin—urinary bladder cancer	0.000119	0.00145	CcSEcCtD
Midazolam—Lethargy—Doxorubicin—urinary bladder cancer	0.000119	0.00145	CcSEcCtD
Midazolam—Hypotension—Fluorouracil—urinary bladder cancer	0.000119	0.00145	CcSEcCtD
Midazolam—Ataxia—Epirubicin—urinary bladder cancer	0.000118	0.00144	CcSEcCtD
Midazolam—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000118	0.00144	CcSEcCtD
Midazolam—ABCB1—female reproductive system—urinary bladder cancer	0.000118	0.00563	CbGeAlD
Midazolam—Cough—Etoposide—urinary bladder cancer	0.000118	0.00144	CcSEcCtD
Midazolam—Tachycardia—Cisplatin—urinary bladder cancer	0.000117	0.00143	CcSEcCtD
Midazolam—Skin disorder—Cisplatin—urinary bladder cancer	0.000117	0.00143	CcSEcCtD
Midazolam—Osteoarthritis—Doxorubicin—urinary bladder cancer	0.000116	0.00142	CcSEcCtD
Midazolam—Diplopia—Doxorubicin—urinary bladder cancer	0.000116	0.00142	CcSEcCtD
Midazolam—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000116	0.00141	CcSEcCtD
Midazolam—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000115	0.0014	CcSEcCtD
Midazolam—Somnolence—Gemcitabine—urinary bladder cancer	0.000115	0.0014	CcSEcCtD
Midazolam—Affect lability—Doxorubicin—urinary bladder cancer	0.000114	0.0014	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000114	0.00139	CcSEcCtD
Midazolam—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000114	0.00139	CcSEcCtD
Midazolam—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000113	0.00138	CcSEcCtD
Midazolam—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000113	0.00138	CcSEcCtD
Midazolam—Somnolence—Fluorouracil—urinary bladder cancer	0.000113	0.00138	CcSEcCtD
Midazolam—Hypotension—Cisplatin—urinary bladder cancer	0.000112	0.00137	CcSEcCtD
Midazolam—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000112	0.00137	CcSEcCtD
Midazolam—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000112	0.00136	CcSEcCtD
Midazolam—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000111	0.00136	CcSEcCtD
Midazolam—Fatigue—Gemcitabine—urinary bladder cancer	0.000111	0.00136	CcSEcCtD
Midazolam—Confusional state—Etoposide—urinary bladder cancer	0.000111	0.00136	CcSEcCtD
Midazolam—Muscular weakness—Epirubicin—urinary bladder cancer	0.000111	0.00135	CcSEcCtD
Midazolam—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000111	0.00135	CcSEcCtD
Midazolam—Pain—Gemcitabine—urinary bladder cancer	0.00011	0.00135	CcSEcCtD
Midazolam—Constipation—Gemcitabine—urinary bladder cancer	0.00011	0.00135	CcSEcCtD
Midazolam—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00011	0.00134	CcSEcCtD
Midazolam—Mood swings—Doxorubicin—urinary bladder cancer	0.00011	0.00134	CcSEcCtD
Midazolam—Asthenia—Thiotepa—urinary bladder cancer	0.00011	0.00134	CcSEcCtD
Midazolam—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00011	0.00134	CcSEcCtD
Midazolam—Ataxia—Doxorubicin—urinary bladder cancer	0.000109	0.00133	CcSEcCtD
Midazolam—Pruritus—Thiotepa—urinary bladder cancer	0.000109	0.00132	CcSEcCtD
Midazolam—Pain—Fluorouracil—urinary bladder cancer	0.000109	0.00132	CcSEcCtD
Midazolam—Paraesthesia—Cisplatin—urinary bladder cancer	0.000108	0.00132	CcSEcCtD
Midazolam—Tachycardia—Etoposide—urinary bladder cancer	0.000108	0.00131	CcSEcCtD
Midazolam—Dyspnoea—Cisplatin—urinary bladder cancer	0.000107	0.00131	CcSEcCtD
Midazolam—Skin disorder—Etoposide—urinary bladder cancer	0.000107	0.00131	CcSEcCtD
Midazolam—ABCB1—vagina—urinary bladder cancer	0.000107	0.00509	CbGeAlD
Midazolam—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000106	0.0013	CcSEcCtD
Midazolam—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000105	0.00128	CcSEcCtD
Midazolam—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000104	0.00127	CcSEcCtD
Midazolam—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000104	0.00127	CcSEcCtD
Midazolam—Drowsiness—Methotrexate—urinary bladder cancer	0.000104	0.00126	CcSEcCtD
Midazolam—Depression—Methotrexate—urinary bladder cancer	0.000103	0.00126	CcSEcCtD
Midazolam—Hypotension—Etoposide—urinary bladder cancer	0.000103	0.00126	CcSEcCtD
Midazolam—Pain—Cisplatin—urinary bladder cancer	0.000103	0.00125	CcSEcCtD
Midazolam—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000103	0.00125	CcSEcCtD
Midazolam—Dizziness—Thiotepa—urinary bladder cancer	0.000101	0.00124	CcSEcCtD
Midazolam—Urticaria—Fluorouracil—urinary bladder cancer	0.000101	0.00123	CcSEcCtD
Midazolam—Feeling abnormal—Cisplatin—urinary bladder cancer	9.91e-05	0.00121	CcSEcCtD
Midazolam—Paraesthesia—Etoposide—urinary bladder cancer	9.9e-05	0.00121	CcSEcCtD
Midazolam—Dyspnoea—Etoposide—urinary bladder cancer	9.83e-05	0.0012	CcSEcCtD
Midazolam—Somnolence—Etoposide—urinary bladder cancer	9.8e-05	0.0012	CcSEcCtD
Midazolam—Vomiting—Thiotepa—urinary bladder cancer	9.76e-05	0.00119	CcSEcCtD
Midazolam—Drowsiness—Epirubicin—urinary bladder cancer	9.69e-05	0.00118	CcSEcCtD
Midazolam—Rash—Thiotepa—urinary bladder cancer	9.67e-05	0.00118	CcSEcCtD
Midazolam—Dermatitis—Thiotepa—urinary bladder cancer	9.67e-05	0.00118	CcSEcCtD
Midazolam—Headache—Thiotepa—urinary bladder cancer	9.61e-05	0.00117	CcSEcCtD
Midazolam—Gastrointestinal disorder—Etoposide—urinary bladder cancer	9.52e-05	0.00116	CcSEcCtD
Midazolam—Fatigue—Etoposide—urinary bladder cancer	9.5e-05	0.00116	CcSEcCtD
Midazolam—Neuropathy peripheral—Epirubicin—urinary bladder cancer	9.5e-05	0.00116	CcSEcCtD
Midazolam—Pain—Etoposide—urinary bladder cancer	9.43e-05	0.00115	CcSEcCtD
Midazolam—Constipation—Etoposide—urinary bladder cancer	9.43e-05	0.00115	CcSEcCtD
Midazolam—Hypersensitivity—Fluorouracil—urinary bladder cancer	9.35e-05	0.00114	CcSEcCtD
Midazolam—Asthenia—Gemcitabine—urinary bladder cancer	9.26e-05	0.00113	CcSEcCtD
Midazolam—Pruritus—Gemcitabine—urinary bladder cancer	9.13e-05	0.00111	CcSEcCtD
Midazolam—Nausea—Thiotepa—urinary bladder cancer	9.11e-05	0.00111	CcSEcCtD
Midazolam—Feeling abnormal—Etoposide—urinary bladder cancer	9.08e-05	0.00111	CcSEcCtD
Midazolam—Pruritus—Fluorouracil—urinary bladder cancer	8.98e-05	0.0011	CcSEcCtD
Midazolam—Drowsiness—Doxorubicin—urinary bladder cancer	8.96e-05	0.00109	CcSEcCtD
Midazolam—Visual impairment—Methotrexate—urinary bladder cancer	8.96e-05	0.00109	CcSEcCtD
Midazolam—Hypersensitivity—Cisplatin—urinary bladder cancer	8.86e-05	0.00108	CcSEcCtD
Midazolam—Bradycardia—Epirubicin—urinary bladder cancer	8.85e-05	0.00108	CcSEcCtD
Midazolam—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	8.79e-05	0.00107	CcSEcCtD
Midazolam—Urticaria—Etoposide—urinary bladder cancer	8.76e-05	0.00107	CcSEcCtD
Midazolam—Eye disorder—Methotrexate—urinary bladder cancer	8.68e-05	0.00106	CcSEcCtD
Midazolam—Asthenia—Cisplatin—urinary bladder cancer	8.63e-05	0.00105	CcSEcCtD
Midazolam—Cardiac disorder—Methotrexate—urinary bladder cancer	8.62e-05	0.00105	CcSEcCtD
Midazolam—Connective tissue disorder—Epirubicin—urinary bladder cancer	8.55e-05	0.00104	CcSEcCtD
Midazolam—Immune system disorder—Methotrexate—urinary bladder cancer	8.39e-05	0.00102	CcSEcCtD
Midazolam—Dizziness—Fluorouracil—urinary bladder cancer	8.39e-05	0.00102	CcSEcCtD
Midazolam—Visual impairment—Epirubicin—urinary bladder cancer	8.38e-05	0.00102	CcSEcCtD
Midazolam—Mediastinal disorder—Methotrexate—urinary bladder cancer	8.37e-05	0.00102	CcSEcCtD
Midazolam—Chills—Methotrexate—urinary bladder cancer	8.34e-05	0.00102	CcSEcCtD
Midazolam—Vomiting—Gemcitabine—urinary bladder cancer	8.21e-05	0.001	CcSEcCtD
Midazolam—Bradycardia—Doxorubicin—urinary bladder cancer	8.19e-05	0.000999	CcSEcCtD
Midazolam—Mental disorder—Methotrexate—urinary bladder cancer	8.14e-05	0.000993	CcSEcCtD
Midazolam—Rash—Gemcitabine—urinary bladder cancer	8.14e-05	0.000993	CcSEcCtD
Midazolam—Dermatitis—Gemcitabine—urinary bladder cancer	8.13e-05	0.000992	CcSEcCtD
Midazolam—Eye disorder—Epirubicin—urinary bladder cancer	8.13e-05	0.000991	CcSEcCtD
Midazolam—Hypersensitivity—Etoposide—urinary bladder cancer	8.12e-05	0.00099	CcSEcCtD
Midazolam—Erythema—Methotrexate—urinary bladder cancer	8.09e-05	0.000987	CcSEcCtD
Midazolam—Headache—Gemcitabine—urinary bladder cancer	8.09e-05	0.000986	CcSEcCtD
Midazolam—Cardiac disorder—Epirubicin—urinary bladder cancer	8.07e-05	0.000984	CcSEcCtD
Midazolam—Vomiting—Fluorouracil—urinary bladder cancer	8.07e-05	0.000984	CcSEcCtD
Midazolam—Rash—Fluorouracil—urinary bladder cancer	8e-05	0.000976	CcSEcCtD
Midazolam—Dermatitis—Fluorouracil—urinary bladder cancer	7.99e-05	0.000975	CcSEcCtD
Midazolam—Headache—Fluorouracil—urinary bladder cancer	7.95e-05	0.00097	CcSEcCtD
Midazolam—Asthenia—Etoposide—urinary bladder cancer	7.91e-05	0.000965	CcSEcCtD
Midazolam—Connective tissue disorder—Doxorubicin—urinary bladder cancer	7.91e-05	0.000964	CcSEcCtD
Midazolam—Immune system disorder—Epirubicin—urinary bladder cancer	7.85e-05	0.000958	CcSEcCtD
Midazolam—Mediastinal disorder—Epirubicin—urinary bladder cancer	7.84e-05	0.000956	CcSEcCtD
Midazolam—Chills—Epirubicin—urinary bladder cancer	7.8e-05	0.000952	CcSEcCtD
Midazolam—Pruritus—Etoposide—urinary bladder cancer	7.8e-05	0.000951	CcSEcCtD
Midazolam—Visual impairment—Doxorubicin—urinary bladder cancer	7.75e-05	0.000946	CcSEcCtD
Midazolam—Nausea—Gemcitabine—urinary bladder cancer	7.67e-05	0.000935	CcSEcCtD
Midazolam—Vomiting—Cisplatin—urinary bladder cancer	7.65e-05	0.000933	CcSEcCtD
Midazolam—Vision blurred—Methotrexate—urinary bladder cancer	7.62e-05	0.00093	CcSEcCtD
Midazolam—Mental disorder—Epirubicin—urinary bladder cancer	7.62e-05	0.000929	CcSEcCtD
Midazolam—Rash—Cisplatin—urinary bladder cancer	7.59e-05	0.000925	CcSEcCtD
Midazolam—Dermatitis—Cisplatin—urinary bladder cancer	7.58e-05	0.000924	CcSEcCtD
Midazolam—Erythema—Epirubicin—urinary bladder cancer	7.57e-05	0.000923	CcSEcCtD
Midazolam—Nausea—Fluorouracil—urinary bladder cancer	7.54e-05	0.000919	CcSEcCtD
Midazolam—Eye disorder—Doxorubicin—urinary bladder cancer	7.52e-05	0.000917	CcSEcCtD
Midazolam—Cardiac disorder—Doxorubicin—urinary bladder cancer	7.47e-05	0.000911	CcSEcCtD
Midazolam—Tension—Epirubicin—urinary bladder cancer	7.43e-05	0.000906	CcSEcCtD
Midazolam—Nervousness—Epirubicin—urinary bladder cancer	7.35e-05	0.000897	CcSEcCtD
Midazolam—Dizziness—Etoposide—urinary bladder cancer	7.29e-05	0.000889	CcSEcCtD
Midazolam—Immune system disorder—Doxorubicin—urinary bladder cancer	7.27e-05	0.000887	CcSEcCtD
Midazolam—Vertigo—Methotrexate—urinary bladder cancer	7.27e-05	0.000886	CcSEcCtD
Midazolam—Mediastinal disorder—Doxorubicin—urinary bladder cancer	7.25e-05	0.000885	CcSEcCtD
Midazolam—Chills—Doxorubicin—urinary bladder cancer	7.22e-05	0.000881	CcSEcCtD
Midazolam—Nausea—Cisplatin—urinary bladder cancer	7.15e-05	0.000872	CcSEcCtD
Midazolam—Vision blurred—Epirubicin—urinary bladder cancer	7.13e-05	0.00087	CcSEcCtD
Midazolam—Cough—Methotrexate—urinary bladder cancer	7.06e-05	0.000861	CcSEcCtD
Midazolam—Mental disorder—Doxorubicin—urinary bladder cancer	7.05e-05	0.00086	CcSEcCtD
Midazolam—Vomiting—Etoposide—urinary bladder cancer	7.01e-05	0.000855	CcSEcCtD
Midazolam—Erythema—Doxorubicin—urinary bladder cancer	7e-05	0.000854	CcSEcCtD
Midazolam—Agitation—Epirubicin—urinary bladder cancer	6.96e-05	0.000849	CcSEcCtD
Midazolam—Rash—Etoposide—urinary bladder cancer	6.95e-05	0.000848	CcSEcCtD
Midazolam—Dermatitis—Etoposide—urinary bladder cancer	6.94e-05	0.000847	CcSEcCtD
Midazolam—Headache—Etoposide—urinary bladder cancer	6.9e-05	0.000842	CcSEcCtD
Midazolam—ABCB1—lymph node—urinary bladder cancer	6.9e-05	0.00329	CbGeAlD
Midazolam—Tension—Doxorubicin—urinary bladder cancer	6.87e-05	0.000838	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	6.84e-05	0.000834	CcSEcCtD
Midazolam—Nervousness—Doxorubicin—urinary bladder cancer	6.8e-05	0.00083	CcSEcCtD
Midazolam—Vertigo—Epirubicin—urinary bladder cancer	6.8e-05	0.00083	CcSEcCtD
Midazolam—Syncope—Epirubicin—urinary bladder cancer	6.79e-05	0.000828	CcSEcCtD
Midazolam—Confusional state—Methotrexate—urinary bladder cancer	6.66e-05	0.000812	CcSEcCtD
Midazolam—Cough—Epirubicin—urinary bladder cancer	6.61e-05	0.000806	CcSEcCtD
Midazolam—Anaphylactic shock—Methotrexate—urinary bladder cancer	6.6e-05	0.000805	CcSEcCtD
Midazolam—Vision blurred—Doxorubicin—urinary bladder cancer	6.6e-05	0.000805	CcSEcCtD
Midazolam—Nausea—Etoposide—urinary bladder cancer	6.55e-05	0.000799	CcSEcCtD
Midazolam—Nervous system disorder—Methotrexate—urinary bladder cancer	6.47e-05	0.00079	CcSEcCtD
Midazolam—Agitation—Doxorubicin—urinary bladder cancer	6.44e-05	0.000785	CcSEcCtD
Midazolam—Anxiety—Epirubicin—urinary bladder cancer	6.42e-05	0.000783	CcSEcCtD
Midazolam—Skin disorder—Methotrexate—urinary bladder cancer	6.41e-05	0.000782	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	6.4e-05	0.000781	CcSEcCtD
Midazolam—Dry mouth—Epirubicin—urinary bladder cancer	6.3e-05	0.000769	CcSEcCtD
Midazolam—Vertigo—Doxorubicin—urinary bladder cancer	6.29e-05	0.000768	CcSEcCtD
Midazolam—Syncope—Doxorubicin—urinary bladder cancer	6.28e-05	0.000766	CcSEcCtD
Midazolam—Confusional state—Epirubicin—urinary bladder cancer	6.23e-05	0.00076	CcSEcCtD
Midazolam—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.18e-05	0.000754	CcSEcCtD
Midazolam—Hypotension—Methotrexate—urinary bladder cancer	6.17e-05	0.000752	CcSEcCtD
Midazolam—Cough—Doxorubicin—urinary bladder cancer	6.11e-05	0.000746	CcSEcCtD
Midazolam—Shock—Epirubicin—urinary bladder cancer	6.08e-05	0.000741	CcSEcCtD
Midazolam—Nervous system disorder—Epirubicin—urinary bladder cancer	6.06e-05	0.000739	CcSEcCtD
Midazolam—Tachycardia—Epirubicin—urinary bladder cancer	6.03e-05	0.000735	CcSEcCtD
Midazolam—Skin disorder—Epirubicin—urinary bladder cancer	6e-05	0.000732	CcSEcCtD
Midazolam—Anxiety—Doxorubicin—urinary bladder cancer	5.94e-05	0.000725	CcSEcCtD
Midazolam—Paraesthesia—Methotrexate—urinary bladder cancer	5.93e-05	0.000723	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	5.92e-05	0.000722	CcSEcCtD
Midazolam—Dyspnoea—Methotrexate—urinary bladder cancer	5.89e-05	0.000718	CcSEcCtD
Midazolam—Somnolence—Methotrexate—urinary bladder cancer	5.87e-05	0.000716	CcSEcCtD
Midazolam—Dry mouth—Doxorubicin—urinary bladder cancer	5.83e-05	0.000711	CcSEcCtD
Midazolam—Dyspepsia—Methotrexate—urinary bladder cancer	5.81e-05	0.000709	CcSEcCtD
Midazolam—Hypotension—Epirubicin—urinary bladder cancer	5.77e-05	0.000704	CcSEcCtD
Midazolam—Confusional state—Doxorubicin—urinary bladder cancer	5.76e-05	0.000703	CcSEcCtD
Midazolam—Anaphylactic shock—Doxorubicin—urinary bladder cancer	5.72e-05	0.000697	CcSEcCtD
Midazolam—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.7e-05	0.000695	CcSEcCtD
Midazolam—Fatigue—Methotrexate—urinary bladder cancer	5.69e-05	0.000694	CcSEcCtD
Midazolam—Pain—Methotrexate—urinary bladder cancer	5.65e-05	0.000689	CcSEcCtD
Midazolam—Shock—Doxorubicin—urinary bladder cancer	5.62e-05	0.000686	CcSEcCtD
Midazolam—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.61e-05	0.000684	CcSEcCtD
Midazolam—Tachycardia—Doxorubicin—urinary bladder cancer	5.58e-05	0.000681	CcSEcCtD
Midazolam—Skin disorder—Doxorubicin—urinary bladder cancer	5.55e-05	0.000677	CcSEcCtD
Midazolam—Paraesthesia—Epirubicin—urinary bladder cancer	5.55e-05	0.000677	CcSEcCtD
Midazolam—Dyspnoea—Epirubicin—urinary bladder cancer	5.51e-05	0.000672	CcSEcCtD
Midazolam—Somnolence—Epirubicin—urinary bladder cancer	5.49e-05	0.00067	CcSEcCtD
Midazolam—Feeling abnormal—Methotrexate—urinary bladder cancer	5.44e-05	0.000664	CcSEcCtD
Midazolam—Dyspepsia—Epirubicin—urinary bladder cancer	5.44e-05	0.000663	CcSEcCtD
Midazolam—Hypotension—Doxorubicin—urinary bladder cancer	5.34e-05	0.000652	CcSEcCtD
Midazolam—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	5.33e-05	0.000651	CcSEcCtD
Midazolam—Fatigue—Epirubicin—urinary bladder cancer	5.33e-05	0.00065	CcSEcCtD
Midazolam—Pain—Epirubicin—urinary bladder cancer	5.28e-05	0.000644	CcSEcCtD
Midazolam—Constipation—Epirubicin—urinary bladder cancer	5.28e-05	0.000644	CcSEcCtD
Midazolam—Urticaria—Methotrexate—urinary bladder cancer	5.24e-05	0.00064	CcSEcCtD
Midazolam—Paraesthesia—Doxorubicin—urinary bladder cancer	5.13e-05	0.000626	CcSEcCtD
Midazolam—Dyspnoea—Doxorubicin—urinary bladder cancer	5.1e-05	0.000622	CcSEcCtD
Midazolam—Feeling abnormal—Epirubicin—urinary bladder cancer	5.09e-05	0.000621	CcSEcCtD
Midazolam—Somnolence—Doxorubicin—urinary bladder cancer	5.08e-05	0.00062	CcSEcCtD
Midazolam—Dyspepsia—Doxorubicin—urinary bladder cancer	5.03e-05	0.000614	CcSEcCtD
Midazolam—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.94e-05	0.000602	CcSEcCtD
Midazolam—Fatigue—Doxorubicin—urinary bladder cancer	4.93e-05	0.000601	CcSEcCtD
Midazolam—Urticaria—Epirubicin—urinary bladder cancer	4.91e-05	0.000599	CcSEcCtD
Midazolam—Pain—Doxorubicin—urinary bladder cancer	4.89e-05	0.000596	CcSEcCtD
Midazolam—Constipation—Doxorubicin—urinary bladder cancer	4.89e-05	0.000596	CcSEcCtD
Midazolam—Hypersensitivity—Methotrexate—urinary bladder cancer	4.86e-05	0.000593	CcSEcCtD
Midazolam—Asthenia—Methotrexate—urinary bladder cancer	4.74e-05	0.000578	CcSEcCtD
Midazolam—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.71e-05	0.000575	CcSEcCtD
Midazolam—Pruritus—Methotrexate—urinary bladder cancer	4.67e-05	0.00057	CcSEcCtD
Midazolam—Hypersensitivity—Epirubicin—urinary bladder cancer	4.55e-05	0.000555	CcSEcCtD
Midazolam—Urticaria—Doxorubicin—urinary bladder cancer	4.54e-05	0.000554	CcSEcCtD
Midazolam—Asthenia—Epirubicin—urinary bladder cancer	4.43e-05	0.000541	CcSEcCtD
Midazolam—Pruritus—Epirubicin—urinary bladder cancer	4.37e-05	0.000533	CcSEcCtD
Midazolam—Dizziness—Methotrexate—urinary bladder cancer	4.37e-05	0.000533	CcSEcCtD
Midazolam—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.21e-05	0.000514	CcSEcCtD
Midazolam—Vomiting—Methotrexate—urinary bladder cancer	4.2e-05	0.000512	CcSEcCtD
Midazolam—Rash—Methotrexate—urinary bladder cancer	4.16e-05	0.000508	CcSEcCtD
Midazolam—Dermatitis—Methotrexate—urinary bladder cancer	4.16e-05	0.000507	CcSEcCtD
Midazolam—Headache—Methotrexate—urinary bladder cancer	4.14e-05	0.000504	CcSEcCtD
Midazolam—Asthenia—Doxorubicin—urinary bladder cancer	4.1e-05	0.0005	CcSEcCtD
Midazolam—Dizziness—Epirubicin—urinary bladder cancer	4.09e-05	0.000498	CcSEcCtD
Midazolam—Pruritus—Doxorubicin—urinary bladder cancer	4.04e-05	0.000493	CcSEcCtD
Midazolam—Vomiting—Epirubicin—urinary bladder cancer	3.93e-05	0.000479	CcSEcCtD
Midazolam—Nausea—Methotrexate—urinary bladder cancer	3.92e-05	0.000478	CcSEcCtD
Midazolam—Rash—Epirubicin—urinary bladder cancer	3.9e-05	0.000475	CcSEcCtD
Midazolam—Dermatitis—Epirubicin—urinary bladder cancer	3.89e-05	0.000475	CcSEcCtD
Midazolam—Headache—Epirubicin—urinary bladder cancer	3.87e-05	0.000472	CcSEcCtD
Midazolam—Dizziness—Doxorubicin—urinary bladder cancer	3.78e-05	0.000461	CcSEcCtD
Midazolam—Nausea—Epirubicin—urinary bladder cancer	3.67e-05	0.000448	CcSEcCtD
Midazolam—Vomiting—Doxorubicin—urinary bladder cancer	3.63e-05	0.000443	CcSEcCtD
Midazolam—Rash—Doxorubicin—urinary bladder cancer	3.6e-05	0.00044	CcSEcCtD
Midazolam—Dermatitis—Doxorubicin—urinary bladder cancer	3.6e-05	0.000439	CcSEcCtD
Midazolam—Headache—Doxorubicin—urinary bladder cancer	3.58e-05	0.000437	CcSEcCtD
Midazolam—Nausea—Doxorubicin—urinary bladder cancer	3.4e-05	0.000414	CcSEcCtD
Midazolam—UGT1A4—Metabolism—NQO1—urinary bladder cancer	1.89e-05	0.000349	CbGpPWpGaD
Midazolam—GABRG3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.88e-05	0.000347	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—GSTO2—urinary bladder cancer	1.87e-05	0.000345	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—NAT1—urinary bladder cancer	1.87e-05	0.000345	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—SLC19A1—urinary bladder cancer	1.87e-05	0.000345	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	1.86e-05	0.000345	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—NAT1—urinary bladder cancer	1.86e-05	0.000345	CbGpPWpGaD
Midazolam—GABRB1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.85e-05	0.000342	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	1.84e-05	0.000339	CbGpPWpGaD
Midazolam—GABRR1—Neuronal System—HRAS—urinary bladder cancer	1.83e-05	0.000338	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	1.83e-05	0.000338	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PRSS3—urinary bladder cancer	1.82e-05	0.000336	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	1.77e-05	0.000327	CbGpPWpGaD
Midazolam—GABRA6—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.75e-05	0.000323	CbGpPWpGaD
Midazolam—GABRQ—Neuronal System—HRAS—urinary bladder cancer	1.75e-05	0.000323	CbGpPWpGaD
Midazolam—GABRR2—Neuronal System—HRAS—urinary bladder cancer	1.75e-05	0.000323	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—UGT2B7—urinary bladder cancer	1.74e-05	0.000323	CbGpPWpGaD
Midazolam—GABRA4—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.73e-05	0.000319	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—UGT2B7—urinary bladder cancer	1.71e-05	0.000316	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	1.71e-05	0.000315	CbGpPWpGaD
Midazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	1.68e-05	0.00031	CbGpPWpGaD
Midazolam—GABRG3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.66e-05	0.000307	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—PPARG—urinary bladder cancer	1.66e-05	0.000306	CbGpPWpGaD
Midazolam—GABRB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.63e-05	0.000302	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	1.62e-05	0.0003	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	1.61e-05	0.000299	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	1.61e-05	0.000297	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—CREBBP—urinary bladder cancer	1.59e-05	0.000294	CbGpPWpGaD
Midazolam—GABRB2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.58e-05	0.000292	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	1.58e-05	0.000292	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—GSTP1—urinary bladder cancer	1.57e-05	0.000291	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—CYP4B1—urinary bladder cancer	1.57e-05	0.00029	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—TYMP—urinary bladder cancer	1.56e-05	0.000289	CbGpPWpGaD
Midazolam—GABRA6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.55e-05	0.000286	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—CYP4B1—urinary bladder cancer	1.54e-05	0.000284	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	1.54e-05	0.000284	CbGpPWpGaD
Midazolam—GABRA5—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.53e-05	0.000284	CbGpPWpGaD
Midazolam—GABRA4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.53e-05	0.000282	CbGpPWpGaD
Midazolam—GABRA3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.51e-05	0.000279	CbGpPWpGaD
Midazolam—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	1.49e-05	0.000276	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	1.48e-05	0.000274	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—SLC19A1—urinary bladder cancer	1.48e-05	0.000274	CbGpPWpGaD
Midazolam—GABRA2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.48e-05	0.000274	CbGpPWpGaD
Midazolam—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.47e-05	0.000272	CbGpPWpGaD
Midazolam—GABRB3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.47e-05	0.000272	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—TYMS—urinary bladder cancer	1.46e-05	0.00027	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—TYMP—urinary bladder cancer	1.45e-05	0.000269	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—SLC19A1—urinary bladder cancer	1.45e-05	0.000269	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	1.45e-05	0.000268	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PRSS3—urinary bladder cancer	1.45e-05	0.000267	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—NCOR1—urinary bladder cancer	1.45e-05	0.000267	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—GSTM1—urinary bladder cancer	1.45e-05	0.000267	CbGpPWpGaD
Midazolam—GABRG2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.44e-05	0.000267	CbGpPWpGaD
Midazolam—GABRG3—Neuronal System—HRAS—urinary bladder cancer	1.44e-05	0.000266	CbGpPWpGaD
Midazolam—GABRB1—Neuronal System—HRAS—urinary bladder cancer	1.42e-05	0.000262	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PRSS3—urinary bladder cancer	1.42e-05	0.000262	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—NAT2—urinary bladder cancer	1.41e-05	0.000261	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	1.41e-05	0.000261	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	1.41e-05	0.000261	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—GSTO2—urinary bladder cancer	1.41e-05	0.00026	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—NAT1—urinary bladder cancer	1.41e-05	0.00026	CbGpPWpGaD
Midazolam—GABRB2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.4e-05	0.000258	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	1.39e-05	0.000257	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—GPX1—urinary bladder cancer	1.38e-05	0.000256	CbGpPWpGaD
Midazolam—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	1.37e-05	0.000254	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—ERCC2—urinary bladder cancer	1.36e-05	0.000251	CbGpPWpGaD
Midazolam—GABRA5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.36e-05	0.000251	CbGpPWpGaD
Midazolam—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.35e-05	0.00025	CbGpPWpGaD
Midazolam—GABRA6—Neuronal System—HRAS—urinary bladder cancer	1.34e-05	0.000248	CbGpPWpGaD
Midazolam—GABRA3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.33e-05	0.000246	CbGpPWpGaD
Midazolam—GABRA4—Neuronal System—HRAS—urinary bladder cancer	1.32e-05	0.000245	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—NAT2—urinary bladder cancer	1.32e-05	0.000243	CbGpPWpGaD
Midazolam—GABRA2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.31e-05	0.000242	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—PTGS2—urinary bladder cancer	1.3e-05	0.000241	CbGpPWpGaD
Midazolam—GABRB3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.3e-05	0.00024	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	1.29e-05	0.000238	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—MTHFR—urinary bladder cancer	1.28e-05	0.000236	CbGpPWpGaD
Midazolam—GABRG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.28e-05	0.000236	CbGpPWpGaD
Midazolam—GABRA1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.26e-05	0.000233	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—RRM2—urinary bladder cancer	1.22e-05	0.000226	CbGpPWpGaD
Midazolam—GABRB2—Neuronal System—HRAS—urinary bladder cancer	1.21e-05	0.000224	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.2e-05	0.000221	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.18e-05	0.000218	CbGpPWpGaD
Midazolam—GABRA5—Neuronal System—HRAS—urinary bladder cancer	1.18e-05	0.000217	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.16e-05	0.000214	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—TYMP—urinary bladder cancer	1.16e-05	0.000214	CbGpPWpGaD
Midazolam—GABRA3—Neuronal System—HRAS—urinary bladder cancer	1.15e-05	0.000213	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.15e-05	0.000213	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—PTEN—urinary bladder cancer	1.14e-05	0.00021	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—RRM2—urinary bladder cancer	1.14e-05	0.00021	CbGpPWpGaD
Midazolam—GABRA2—Neuronal System—HRAS—urinary bladder cancer	1.13e-05	0.00021	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—TYMP—urinary bladder cancer	1.13e-05	0.000209	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	1.13e-05	0.000209	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—ENO2—urinary bladder cancer	1.13e-05	0.000209	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—TYMP—urinary bladder cancer	1.13e-05	0.000209	CbGpPWpGaD
Midazolam—GABRB3—Neuronal System—HRAS—urinary bladder cancer	1.13e-05	0.000208	CbGpPWpGaD
Midazolam—GABRA1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.12e-05	0.000206	CbGpPWpGaD
Midazolam—GABRG2—Neuronal System—HRAS—urinary bladder cancer	1.11e-05	0.000205	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	1.1e-05	0.000203	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.09e-05	0.000202	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—EP300—urinary bladder cancer	1.08e-05	0.0002	CbGpPWpGaD
Midazolam—SLC22A1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.08e-05	0.0002	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.07e-05	0.000197	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—HPGDS—urinary bladder cancer	1.05e-05	0.000194	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—ENO2—urinary bladder cancer	1.05e-05	0.000194	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—NAT2—urinary bladder cancer	1.05e-05	0.000193	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.04e-05	0.000193	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—PPARG—urinary bladder cancer	1.04e-05	0.000191	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—NAT2—urinary bladder cancer	1.02e-05	0.000189	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—NAT2—urinary bladder cancer	1.02e-05	0.000189	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—GSTT1—urinary bladder cancer	1.02e-05	0.000189	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.01e-05	0.000187	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.01e-05	0.000186	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—CREBBP—urinary bladder cancer	9.95e-06	0.000184	CbGpPWpGaD
Midazolam—GABRA1—Neuronal System—HRAS—urinary bladder cancer	9.67e-06	0.000179	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	9.6e-06	0.000177	CbGpPWpGaD
Midazolam—SLC22A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	9.55e-06	0.000177	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	9.33e-06	0.000173	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	9.14e-06	0.000169	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—NQO1—urinary bladder cancer	9.11e-06	0.000168	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—RRM2—urinary bladder cancer	9.02e-06	0.000167	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—RRM2—urinary bladder cancer	8.84e-06	0.000163	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—RRM2—urinary bladder cancer	8.82e-06	0.000163	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	8.67e-06	0.00016	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—NAT1—urinary bladder cancer	8.67e-06	0.00016	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—TYMP—urinary bladder cancer	8.52e-06	0.000158	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—NQO1—urinary bladder cancer	8.48e-06	0.000157	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	8.36e-06	0.000155	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	8.36e-06	0.000154	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—ENO2—urinary bladder cancer	8.36e-06	0.000154	CbGpPWpGaD
Midazolam—SLC22A1—Neuronal System—HRAS—urinary bladder cancer	8.28e-06	0.000153	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	8.18e-06	0.000151	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—ENO2—urinary bladder cancer	8.18e-06	0.000151	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	8.18e-06	0.000151	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	8.17e-06	0.000151	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—ENO2—urinary bladder cancer	8.17e-06	0.000151	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—PTGS2—urinary bladder cancer	8.15e-06	0.000151	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	8.1e-06	0.00015	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	7.94e-06	0.000147	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	7.93e-06	0.000147	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	7.92e-06	0.000146	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	7.79e-06	0.000144	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	7.73e-06	0.000143	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—NAT2—urinary bladder cancer	7.71e-06	0.000143	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	7.6e-06	0.00014	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	7.14e-06	0.000132	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—PTEN—urinary bladder cancer	7.1e-06	0.000131	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—GSTP1—urinary bladder cancer	7.07e-06	0.000131	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—TYMS—urinary bladder cancer	7.06e-06	0.000131	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	6.98e-06	0.000129	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	6.98e-06	0.000129	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6.87e-06	0.000127	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—EP300—urinary bladder cancer	6.78e-06	0.000125	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	6.74e-06	0.000125	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—NQO1—urinary bladder cancer	6.73e-06	0.000125	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—GPX1—urinary bladder cancer	6.68e-06	0.000124	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—RRM2—urinary bladder cancer	6.65e-06	0.000123	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—NQO1—urinary bladder cancer	6.6e-06	0.000122	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—NQO1—urinary bladder cancer	6.58e-06	0.000122	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—TYMS—urinary bladder cancer	6.57e-06	0.000121	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	6.57e-06	0.000121	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	6.56e-06	0.000121	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—NCOR1—urinary bladder cancer	6.5e-06	0.00012	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—GSTM1—urinary bladder cancer	6.5e-06	0.00012	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—GPX1—urinary bladder cancer	6.22e-06	0.000115	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	6.17e-06	0.000114	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—ENO2—urinary bladder cancer	6.16e-06	0.000114	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—HPGDS—urinary bladder cancer	6.16e-06	0.000114	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—ERCC2—urinary bladder cancer	6.11e-06	0.000113	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—GSTT1—urinary bladder cancer	5.98e-06	0.000111	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—MTHFR—urinary bladder cancer	5.74e-06	0.000106	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	5.62e-06	0.000104	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.6e-06	0.000103	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	5.5e-06	0.000102	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	5.49e-06	0.000102	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—TYMP—urinary bladder cancer	5.25e-06	9.71e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—TYMS—urinary bladder cancer	5.22e-06	9.66e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	5.16e-06	9.54e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	5.16e-06	9.54e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—TYMS—urinary bladder cancer	5.11e-06	9.46e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—TYMS—urinary bladder cancer	5.1e-06	9.44e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	5.06e-06	9.35e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	5.06e-06	9.35e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	5.05e-06	9.33e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	5.05e-06	9.33e-05	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—PPARG—urinary bladder cancer	5e-06	9.25e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—NQO1—urinary bladder cancer	4.97e-06	9.18e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—GPX1—urinary bladder cancer	4.94e-06	9.14e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	4.85e-06	8.97e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—GPX1—urinary bladder cancer	4.84e-06	8.95e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—GPX1—urinary bladder cancer	4.83e-06	8.93e-05	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	4.81e-06	8.88e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	4.75e-06	8.79e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.75e-06	8.78e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	4.74e-06	8.77e-05	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PPARG—urinary bladder cancer	4.66e-06	8.61e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	4.56e-06	8.43e-05	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	4.47e-06	8.27e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	4.47e-06	8.26e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	4.46e-06	8.24e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—GSTP1—urinary bladder cancer	4.14e-06	7.66e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—RRM2—urinary bladder cancer	4.1e-06	7.58e-05	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	3.94e-06	7.28e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—TYMS—urinary bladder cancer	3.85e-06	7.12e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—NCOR1—urinary bladder cancer	3.81e-06	7.04e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—GSTM1—urinary bladder cancer	3.81e-06	7.04e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.8e-06	7.02e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.8e-06	7.02e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PPARG—urinary bladder cancer	3.7e-06	6.84e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.68e-06	6.81e-05	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	3.66e-06	6.77e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—GPX1—urinary bladder cancer	3.65e-06	6.74e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PPARG—urinary bladder cancer	3.62e-06	6.7e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PPARG—urinary bladder cancer	3.62e-06	6.69e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—ERCC2—urinary bladder cancer	3.58e-06	6.62e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	3.55e-06	6.57e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	3.48e-06	6.44e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	3.47e-06	6.42e-05	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—PTEN—urinary bladder cancer	3.43e-06	6.34e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—MTHFR—urinary bladder cancer	3.36e-06	6.22e-05	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—EP300—urinary bladder cancer	3.27e-06	6.05e-05	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PTEN—urinary bladder cancer	3.19e-06	5.9e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.06e-06	5.66e-05	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—EP300—urinary bladder cancer	3.05e-06	5.63e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	2.91e-06	5.38e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	2.85e-06	5.27e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	2.84e-06	5.26e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PPARG—urinary bladder cancer	2.73e-06	5.04e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—CREBBP—urinary bladder cancer	2.62e-06	4.85e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.55e-06	4.72e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PTEN—urinary bladder cancer	2.54e-06	4.69e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PTEN—urinary bladder cancer	2.49e-06	4.6e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PTEN—urinary bladder cancer	2.48e-06	4.59e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—EP300—urinary bladder cancer	2.42e-06	4.47e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.37e-06	4.39e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—EP300—urinary bladder cancer	2.37e-06	4.38e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—EP300—urinary bladder cancer	2.37e-06	4.37e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.35e-06	4.34e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.35e-06	4.34e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.25e-06	4.15e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.21e-06	4.08e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.15e-06	3.97e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.07e-06	3.83e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.87e-06	3.46e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—EP300—urinary bladder cancer	1.79e-06	3.3e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.68e-06	3.11e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.61e-06	2.99e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.32e-06	2.44e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.15e-06	2.13e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.1e-06	2.03e-05	CbGpPWpGaD
